Novartis Pharmaceuticals Corporation v. West-Ward Pharmaceuticals International Limited
1:15-cv-00474
Overview
Parties
Defendant
West-Ward Pharmaceuticals International Limited NPE (University / Research)
Represented By
14 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Novartis AG Operating Company
Represented By
4 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Novartis Pharmaceuticals Corporation Operating Company
Represented By
6 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 11 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | Asserted Patent | View Official Patent → |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🇪🇺 European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Hikma Pharmaceuticals PLC v. Novartis Pharmaceuticals Corporation
Breckenridge Pharmaceutial, Inc. v. Novartis Pharmaceuticals Corporation
West-Ward Pharmaceuticals International Limited v. Novartis AG
Argentum Pharmaceuticals LLC et al. v. Novartis AG
Par Pharmaceutical, Inc. et al. v. Novartis AG
Roxane Laboratories, Inc. et al. v. Novartis AG
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9006224
Neuroendocrine tumor treatment
|
Filed: 2006-11-20
Issued: 2015-04-14
|
Active (1.6 yrs remaining)
+589d PTA
Expires: 2028-07-01
|
|
|
US8410131
Cancer treatment
|
Filed: 2002-02-18
Issued: 2013-04-02
|
Expired (Term Ended)
+1352d PTA
Expires: 2025-11-01
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+589 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
5
Dispositive
0
Granted
0
Denied
0
Pending / Review
5
Motions by Category
Key Dispositive Motions & Rulings